OPRTUNTI: Offering Potential for Reproduction Through Transplantation of Uterus iN the Treatment of Infertility
This research study will use uterus transplantation to treat uterine factor infertility, also known as the inability to bear children due to not having a uterus. The purpose of this study is to enable women seeking genetically-related children and the childbearing experience to experience pregnancy and birth a child. In this study, living donors will undergo surgery to give the donor's uterus to another woman. The woman who receives the transplant will take immunosuppression to keep the uterus and herself healthy. Because taking immunosuppressive medicine has side effects, uterus transplantation is intended to be temporary, lasting about 5 years. The goals of the study are successful pregnancy and the birth of one, and possibly two, healthy babies per transplant patient. The uterus is to be removed and immunosuppression stopped following the birth of a child. Offspring are delivered by Caesarian section, at which time the transplant may also be removed. Transplant candidates must have fertilized, frozen (cryopreserved) embryos at a Johns Hopkins facility before undergoing transplantation. Transplant candidates will be asked to identify candidates' potential uterus donor. Altruistic donors, or women who want to donate without knowing a potential recipient, may also participate. All potential donors will be screened to see if the donors are a good match for a recipient and are healthy enough to have the donation surgery. Study Duration: * Uterus Donors: Screening through about 12 months following the transplant operation. * Uterus Recipients: Recipients may have the uterus for about 5 years. After the transplant is removed, the study team will ask for yearly follow-ups for another 5 years. * Children born from transplanted uteruses: The study team asks to follow offspring yearly through age 21 years.
‣ Recipient Inclusion Criteria:
• Genotypic female of any race, color, or ethnicity.
• Uterine factor infertility.
• Aged 18-38 years at time of egg retrieval.
• Strong desire to undergo uterus transplant in order to become pregnant and give birth to a child.
• Embryo cryopreservation with embryos located at Johns Hopkins:
⁃ Has a minimum of 4-8 cryopreserved normal embryos following Preimplantation Genetic Screening (PGS-screening).
‣ OR o Is willing to undergo egg retrieval, in vitro fertilization, and PGS-screening to cryopreserve a minimum of 4-8 normal embryos.
• Willingness to undergo embryo implantation after uterus transplantation to achieve pregnancy.
• In the opinion of the study team, makes a reasonable effort to identify and refer her own potential uterus donor to the study team.
• Completes the protocol informed consent form.
• Non-smoker, defined by having never smoked or having quit \>6 consecutive months prior to screening.
• No co-existing medical condition which, in the opinion of the study team, could affect the immunosuppression protocol, surgical procedure, or ability to be pregnant or bear a child. (See Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of uterus transplantation.)
• Negative serum pregnancy test.
• Blood type compatible with donor.
• Negative crossmatch with donor.
• Patient agrees to comply with the protocol and states a dedication to the treatment regime.
• Agrees to uterus explanation following birth of a child and or 5 years without successful pregnancy.
‣ Donor Inclusion Criteria:
• Genotypic female with an intact uterus.
• Medical history includes known successful pregnancy (e.g., gravid uterus).
• Aged 25 - 65 years.
• Consents to uterus donation and required pre-donation screening.
• For females of child-bearing potential: Negative serum pregnancy test.
• Blood type compatible with recipient.
• Negative crossmatch with recipient.
‣ Donor and Recipient Inclusion Criteria:
• USA citizen or equivalent.
• No co-existing psycho-social problems (i.e., alcoholism, drug abuse).
• BMI ≤35
• o A higher BMI may be accepted at the discretion of the study team.
• Negative for HIV at transplant.
• Negative for malignancy for past 5 years.